BCL2 inhibitors are a form of targeted cancer therapy. They prompt cancer cells to die by altering the interactions among key proteins within those cells. Learn more about how BCL2 inhibitors work: http://ms.spr.ly/6183lOoHf | Dana-Farber Cancer Institute

How did an interesting discovery of a protein called Bcl-2 become a game-changing cancer drug? It’s a story that started decades ago in the lab of the late Stanley Korsmeyer, MD. And it highlights the persistence and momentum needed today in cancer research, which lies behind the discovery of Venetoclax. Listen to the story in a minute or find the full podcast at http://ms.spr.ly/618897MbA or wherever you get your podcasts. | Dana-Farber Cancer Institute